Regener-Eyes® Ophthalmic Solution: A New Therapeutic Agent to Relieve Dryness of the Eye for Tear Hyperosmolarity-Induced Pathological Changes in the Eyes of Patients Suffering From Dry Eye Discomfort

Abstract

Tear hyperosmolarity is an initial and crucial step in the development, progression and aggravation of dry eye discomfort. Decreased tear secretion or altered tear composition leads to tear film instability/imbalance which in Dry Eye (DE) patients results in abnormally rapid breakup of the tear film after blinking. Numerous structural changes in epithelial cells and mucin-producing goblet cells develop as a consequence of exposition of these cells to the hyperosmolar tears. Tear hyperosmolarity causes oxidative stress, disruption of DNA repair system and induces DNA damage in the cells of ocular surface and lacrimal system, leading to their apoptosis. An injury of lacrimal glands results in decreased tear secretion, enabling the creation of “positive loop” that leads to the DE progression and aggravation. Accordingly, eye drops, which alleviate tear hyperosmolarity and restore tear homeostasis at corneal surface, will break up vicious DEcycle and will relieve eye pain, irritation, discomfort, and vision disturbance in DE patients. Regener-Eyes® Ophthalmic Solution is a hypotonic solution enriched with osmoprotectants (that address the hyperosmolarity of a tear film), which helps support tear stability and contribute to relieve dryness of the eye in DE patients. In this article, we summarized current knowledge and future perspectives about topical administration of Regener-Eyes® Ophthalmic Solution to relieve dryness of the eye in DE patients.